Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026
Summary
Dry Eye Syndrome DES is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. With a rapidly accelerating worldwide prevalence and the limited treatment options available, there is a growing pressure for new therapies and curative treatment for DES patients. Significant efforts are being made to develop a new treatment for DES, as current pharmacologic management is known to only provide temporary symptomatic relief.
GlobalData estimates the 2016 sales for DES at approximately $2.2B across the 8MM covered in this report.
The DES pipeline activity comprises 10 active Phase III or Phase II/III pipeline agents with novel mechanisms of action as well as cyclosporines with improved clinical profiles. Additionally, six of these latestage pipeline drugs are expected to be firstinclass therapies. The most notable pipeline drugs include RegeneRx's thymosin beta4 product RGN259, Aldeyra's reproxalap which acts as an aldehyde trap, and Sylentis' TRPV1 inhibitor tivanisiran. Other latephase novel drugs include Mitotech's mitochondrial antioxidant product visomitin, Kala Pharmaceuticals' corticosteroid KPI121, and Novartis' and Dompe's recombinant human lubricin protein ECF843. GlobalData expects these new drugs will expand the DES treatment options and contribute to overall market growth. Nevertheless, considerable opportunities remain within this severely underserved DES market.
Key Questions Answered
What are the key unmet needs clinically and in research? What do KOLs identify as the key unmet needs? Will the products in the DES pipeline fill these unmet needs?
When are the pipeline products expected to launch? What are the key features of the products in the pipeline?
What are the threats for drugs currently on the market? How will the new pipeline products be incorporated into the current treatment algorithm?
What are the key hurdles for manufacturers entering the DES market?
Scope
Overview of DES: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized DES market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments including mild DES, moderate DES, and severe DES, forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidate in Phase III and Phase II/III development is profiled.
Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to
Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.